Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease

Neurology. 2007 May 1;68(18):1455-9. doi: 10.1212/01.wnl.0000260605.12506.86.

Abstract

Objective: To compare acute and chronic effects of l-dopa on bladder function in levodopa-naive Parkinson disease (PD) patients who had urinary urgency.

Methods: We evaluated 26 l-dopa-naive PD patients at a university-based PD center with a first urodynamic session with a double examination: in the off treatment condition and 1 hour after acute challenge with carbidopa/l-dopa 50/200 mg; then, a chronic l-dopa monotherapy was administered (mean dose 300 +/- 150 mg). Two months later, patients underwent a second urodynamic session with a single evaluation 1 hour after the acute carbidopa/l-dopa challenge.

Results: The first acute l-dopa challenge significantly worsened bladder overactivity (neurogenic overactive detrusor contractions threshold [NDOC-t; 32% of worsening] and bladder capacity [BC; 22% of worsening]); on the contrary, l-dopa challenge during chronic administration ameliorated the first sensation of bladder filling (FS; 120% of improvement), NDOCT-t (93% improvement), and BC (33% of improvement) vs the values obtained with acute administration. An 86% significant improvement of FS in comparison with the basal value was observed.

Conclusions: The acute and chronic l-dopa effects may be due to the different synaptic concentrations or to the activation of postsynaptic mechanisms obtained by chronic administration.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Acute Disease / therapy
  • Carbidopa / administration & dosage
  • Carbidopa / adverse effects
  • Chronic Disease / therapy
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / adverse effects
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypogastric Plexus / drug effects
  • Hypogastric Plexus / physiopathology
  • Levodopa / administration & dosage*
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Parasympathetic Fibers, Postganglionic / drug effects
  • Parasympathetic Fibers, Postganglionic / physiopathology
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Treatment Outcome
  • Urinary Bladder / drug effects
  • Urinary Bladder / innervation
  • Urinary Bladder / physiopathology
  • Urinary Bladder, Neurogenic / chemically induced*
  • Urinary Bladder, Neurogenic / drug therapy*
  • Urinary Bladder, Neurogenic / physiopathology
  • Urination Disorders / chemically induced
  • Urination Disorders / drug therapy
  • Urination Disorders / physiopathology

Substances

  • Dopamine Agents
  • Levodopa
  • Carbidopa